ATORVASTATIN-AS atorvastatin (as calcium) 20 mg film-coated tablet blister pack

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

atorvastatin calcium, Quantity: 20.68 mg (Equivalent: atorvastatin, Qty 20 mg)

Pieejams no:

Medis Pharma Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

Atorvastatin calcium

Zāļu forma:

Tablet, film coated

Kompozīcija:

Excipient Ingredients: magnesium stearate; colloidal anhydrous silica; activated attapulgite; microcrystalline cellulose; pregelatinised maize starch; hyprolose; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000

Ievadīšanas:

Oral

Vienības iepakojumā:

10, 20, 40, 50, 30

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

As an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,Indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see CLINICAL TRIALS, Prevention of Cardiovascular Disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Produktu pārskats:

Visual Identification: White, oval bi-convex tablets with breakline on one side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Autorizācija statuss:

Registered

Autorizācija datums:

2011-09-16